Skip to Main Content

A Cambridge, Mass., biotech startup working to unlock new applications for cell therapies — particularly for type 1 diabetes — is getting new leadership.

Dr. Rogerio Vivaldi, formerly at Sanofi’s Bioverativ, took the helm of of Sigilon Therapeutics on Aug. 1, the company announced Tuesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!